These studies using GnRH antagonists showed significant improvement of lower urinary tract symptoms (LUTS) in patients with BPH; specifically, they exhibited changes in the International Prostate Symptom Score (IPSS) and urinary flow (Qmax) [18]. This evidence concerns the gene GNRH1 and benign prostatic hyperplasia.